Abstract
Over the past 20 years, there have been significant advances in cancer treatment with the introduction of targeted therapies, which are often used in combination. These treatments are important for many patients due to prolonged survival compared to existing standard of care. However, patient access to combinations has proved difficult, especially when: the constituents are produced by different manufacturers and the constituents are used in multiple indications. Challenges include difficulties in attributing the value of the constituents in the combination and where value and price is not a simple sum of the parts as well as structural limitations of the access process (such as, legal framework and considerations around manufacturers jointly participating in price negotiations).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
